Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Ranthe

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Heart (British Cardiac Society)|September 20, 2015
Miscarriage and cardiovascular diseaseM F Ranthe, H A Boyd
Diabetic Medicine : a Journal of the British Diabetic Association|November 10, 2019
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulinL Meneghini, A Doshi, D Gouet, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Heart (British Cardiac Society)|September 20, 2015
Miscarriage and cardiovascular diseaseM F Ranthe, H A Boyd
Diabetic Medicine : a Journal of the British Diabetic Association|November 10, 2019
Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulinL Meneghini, A Doshi, D Gouet, et al.
Pageof 1